Dr. Arturo Molina is a seasoned medical executive and former Chief Medical Officer at Sutro Biopharma, a biotech company focused on developing medicines for cancer. He has a robust background in oncology, having held significant roles at major firms like...

Dr. Arturo Molina is a seasoned medical executive and former Chief Medical Officer at Sutro Biopharma, a biotech company focused on developing medicines for cancer. He has a robust background in oncology, having held significant roles at major firms like Johnson & Johnson and Biogen. His work has often been at the intersection of medical innovation and business, making him a key player in drug development strategies. Notably, he resigned in November 2022, but his contributions helped shape Sutro's clinical direction. He holds an M.D. and an M.S. and is board certified in internal medicine and medical oncology. Arturo's leadership has been grounded in achieving corporate goals, which he demonstrated in his compensation structures tied closely to performance metrics, mainly focusing on research and clinical milestones. His history of insider trading shows strategic selling and buying within the company, reflecting his confidence in its future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

S

Dr. Arturo Molina

Ex-CEO of Sutro Biopharma

Sector of Economy

Healthcare

CEO of Sutro Biopharma for

1 year 10 months (Jan 2021 - Nov 2022)

Previous Experience

Chief Medical Officer at Sutro Biopharma, Inc.

Rivals

Competitors/colleagues of Dr. Arturo Molina

Holdings

See how much did Dr. Arturo Molina make over time.

During his time at Sutro Biopharma, Dr. Arturo Molina's holdings fluctuated significantly, revealing a keen sense for market timing. He began with modest transactions in 2019, such as buying shares worth $214.49K and steadily increased his investments, reaching as high...

During his time at Sutro Biopharma, Dr. Arturo Molina's holdings fluctuated significantly, revealing a keen sense for market timing. He began with modest transactions in 2019, such as buying shares worth $214.49K and steadily increased his investments, reaching as high as $1.74M by January 2024. The peak in his trading came in March 2023, when he sold shares valuing over $1.26M, showcasing his strategic moves in line with the company's growth phases. This trend indicates that his wealth is closely tied to the company's performance and potential—reflecting investor optimism about biopharma prospects.

Total Stock Sold

$30.10K

PTGX

$30.10K

1,848 PTGX shares

What if they kept their stock?

If Dr. Arturo Molina didn't sell their stock, today they would have:
Extra PTGX1,848 shares worth $12.90K.
This is -57.15% and $17.20K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Arturo Molina.

PTGX

26,250 shares

PTGX

Nov 15, 2023

Received

PTGX

$30.01K

PTGX at $16.24/share

Nov 15, 2023

Sale

PTGX

3,125 shares

PTGX

Jan 16, 2023

Received

PTGX

21,250 shares

PTGX

Nov 15, 2022

Received

STRO

$50.00K

STRO at $7.75/share

May 14, 2020

Purchase

Compensation History

See how much did Dr. Arturo Molina make over time.

In terms of compensation, Dr. Molina's financial rewards were performance-driven, a strategy that aligns with many executives in the biotech field. In 2022, his total compensation stood at $1,077,767, which included a $662,500 salary and a $402,000 bonus based on hitting corporate goals. The bonus reflected a 100% achievement level of set objectives. Interestingly, he received no vested stock in 2022, indicating a focus on performance-based awards rather than immediate payouts. In 2021, his total compensation was lower at $645,827, yet still showed a significant focus on achieving clinical and strategic targets, which are critical in the fast-paced biopharma industry. His compensation philosophy emphasizes that top executives should earn their pay through tangible results, further underlining the importance of measurable corporate goals.

Year

2022

Total Compensation

$1.07M

Salary

$662.50K

Board Justification

The compensation philosophy emphasizes pay for performance, aligning executive compensation with company performance and market practices.

Bonus

$402.00K

Board Justification

The bonus is based on the achievement of corporate goals set by the Compensation Committee, with an overall achievement level of 100% for 2022.

Other

$8.27K

Board Justification

Other compensation includes health benefits and other minor compensations.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2022 for the CEO.

Performance Metrics

The performance metrics include achievement of corporate goals related to development, research, financial, and operational milestones.